Stevens-johnson syndrome after armodafnil use

Abstract

We present the case of a 21-year-old woman in whom Stevens-Johnson syndrome (SJS) developed after initiation of armodafnil. Although this rare and life-threatening reaction is listed on armodafnil's label, no cases have been reported in the literature. This case, in addition to an update of the drug's label after post-marketing research, both support the link between armodafnil and SJS. Providers should maintain a high clinical suspicion for SJS when starting therapy to minimize associated morbidity and mortality by discontinuing armodafnil at the onset of frst symptoms.